Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT00033631 · ClinicalTrials.gov registry record · Phase 3
Radiation Therapy in Treating Patients With Stage II Prostate Cancer
A Phase 3 study of Prostate Cancer, sponsored by Radiation Therapy Oncology Group.
- Completed
- Registry status
- Phase 3
- Development phase
- 1,534
- Enrollment target
- 20
- Study locations
NCT00033631: Completed Phase 3 study of Prostate Cancer, sponsored by Radiation Therapy Oncology Group.
NCT00033631 is a Phase 3 study of Prostate Cancer that has completed, run by Radiation Therapy Oncology Group. The registered enrollment target is 1,534 participants, above the 606-participant average among 735 other Prostate Cancer trials with a reported enrollment target (153% higher). The trial reports 20 study locations across 9 states. According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT00033631, a Phase 3 study of Prostate Cancer, has completed, sponsored by Radiation Therapy Oncology Group.
- COMPLETED
- Registry status
- Phase 3
- Development phase
- 1,534 participants
- Enrollment target
- 20
- Study locations
Study Summary
RATIONALE: Specialized radiation therapy that delivers a high dose of radiation directly to the tumor may kill more tumor cells and cause less damage to normal tissue. It is not yet known which dose of radiation therapy is more effective in treating stage II prostate cancer. PURPOSE: Randomized phase III trial to compare the effectiveness of two different doses of specialized radiation therapy in treating patients who have stage II prostate cancer.
Primary Outcome
Survival time is defined as time from randomization to the date of death from any cause and is estimated by the Kaplan-Meier Method. Patients last know to be alive are censored at date of last contact.
Conditions Studied
Interventions
- RADIATION 70.2 Gy 3D-CRT/IMRT
- RADIATION 79.2 Gy 3D-CRT/IMRT
Study Locations (20)
Kansas
- Providence Medical Center - Kansas City
- Lawrence Memorial Hospital - Lawrence
- Menorah Medical Center - Overland Park
- Johnson County Radiation Therapy - Overland Park
- Shawnee Mission Medical Center - Shawnee Mission
Michigan
- Veterans Affairs Medical Center - Ann Arbor - Ann Arbor
- University of Michigan Comprehensive Cancer Center - Ann Arbor
- Foote Memorial Hospital - Jackson
- West Michigan Cancer Center - Kalamazoo
California
- Veterans Affairs Medical Center - Long Beach - Long Beach
- Radiological Associates of Sacramento Medical Group, Incorporated - Sacramento
- UCSF Helen Diller Family Comprehensive Cancer Center - San Francisco
Indiana
- Oncology Center at Saint Margaret Mercy Healthcare Center - Hammond
- Cancer Center at Ball Memorial Hospital - Muncie
Maryland
- Greenebaum Cancer Center at University of Maryland Medical Center - Baltimore
- Central Maryland Oncology Center - Columbia
District of Columbia
- Washington Cancer Institute at Washington Hospital Center - Washington D.C.
Florida
- Bay Medical - Panama City
Illinois
- Methodist Medical Center of Illinois - Peoria
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 1,534 participants |
| Start Date | 2002-03 |
| Est. Completion | 2022-12-22 |
| Phase | Phase 3 |
What the finished NCT00033631 record still lists
NCT00033631 is an interventional study that assigns participants to a tested intervention. Its 1,534 participants enrollment target places it among the larger protocols in the corpus, above the 606-participant average among 735 other Prostate Cancer trials with a reported enrollment target (153% higher).
The record links to 1 condition, with Prostate Cancer appearing as the primary indexed condition, and to 2 interventions - of which 70.2 Gy 3D-CRT/IMRT is the first listed.
NCT00033631 names 20 study sites across 9 states, led by Kansas, Michigan, California.
Frequently Asked Questions
What is clinical trial NCT00033631 about?
NCT00033631 is a clinical study titled "Radiation Therapy in Treating Patients With Stage II Prostate Cancer". RATIONALE: Specialized radiation therapy that delivers a high dose of radiation directly to the tumor may kill more tumor cells and cause less damage to normal tissue. It is not yet known which dose of radiation therapy is more effective in treating stage II prostate cancer. PURPOSE: Randomized pha...
What is the current status of trial NCT00033631?
This trial is currently completed. It is a Phase 3 study. The enrollment target is 1,534 participants. The study started on 2002-03. Estimated completion is 2022-12-22.
What conditions does trial NCT00033631 study?
This clinical trial studies the following conditions: Prostate Cancer.
What interventions are being tested in trial NCT00033631?
The interventions under investigation include: 70.2 Gy 3D-CRT/IMRT (RADIATION), 79.2 Gy 3D-CRT/IMRT (RADIATION).
Who is sponsoring clinical trial NCT00033631?
This trial is sponsored by Radiation Therapy Oncology Group, which has 144 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT00033631 being conducted?
This trial has 20 study locations across California, District of Columbia, Florida, Illinois, Indiana. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Similar trials for Prostate Cancer
Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.
Where NCT00033631's enrollment target sits among peer trials
1,534 34th of 735 higher than 702 of 735 other Prostate Cancer trials
participants (enrollment target), bucketed by value
Each bar is a band; taller bars hold more other Prostate Cancer trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.
Source ClinicalTrials.gov registry export · 2026-08-08
-
Copper Cu 64 PSMA I&T PET Imaging in Men With Newly Diagnosed Prostate Cancer
RECRUITING · Phase 3
-
PROSTATE-IQ: Parallel RandOmized STudy of Personalized Apalutamide Treatment and Evaluation to Improve Quality of Life in Post-Operative Radiation With Androgen Axis Suppression. A Phase III Multi-center Study for Men With Detectable PSA After Prostatectomy for Prostate Cancer.
RECRUITING · Phase 3
-
Androgen Suppression Combined With Nodal Irradiation and Dose Escalated Prostate Treatment
RECRUITING · Phase 3
-
Robotic Opioid-free Prostatectomy Enhanced Strategy (ROPES)
RECRUITING · Phase 3
-
SAFE Nerve Sparing Guided by Micro-ultrasound (MUS)
RECRUITING · Phase 3
-
Adjuvant Curcumin to Assess Recurrence Free Survival in Patients Who Have Had a Radical Prostatectomy
RECRUITING · Phase 3
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar enrollment target
- NCT06842875 · 1,536 participants · NA
Rhode Island - Statewide Postpartum Hypertension Remote Surveillance
- NCT06393374 · 1,530 participants · Phase 3
Sacituzumab Tirumotecan (MK-2870) Plus Pembrolizumab Versus TPC in TNBC Who Did Not Achieve pCR (MK-2870-012)
- NCT07114510 · 1,530 participants · NA
Optimal Ventilation for Cardiac Arrest
- NCT06623097 · 1,528 participants · NA
Exercise and Nutrition for Older Cancer Survivors and Their Support Person: The Vitality Study
Similar registry start date
- NCT05988463 · started 2027-01-01 · Phase 1
Dose-Escalation Study of Artesunate Patients With IPF
- NCT07219706 · started 2026-12-10 · NA
Dietary Fiber and Time Restricted Eating
- NCT02831335 · started 2026-12-01
Technical Development of Multi-Parametric Renocerebral MRI
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia